

Mapping a Path to Market: Creating a Comprehensive Drug Development Strategy

OVERVIEW »







SUCCESS RATES FOR DRUGS IN CLINICAL DEVELOPMENT ² »

Q

000

81


of medicines EMA recommended for approval³

2013

Ο

0

AVERAGE COST TO DEVELOP A DRUG (INCLUDING COST OF FAILURES)^{1, 2} »



THE FOUNDATION OF A COMPREHENSIVE DRUG DEVELOPMENT STRATEGY »

DRUG DEVELOPMENT HAS BEEN DESCRIBED AS THE PROCESS OF OBTAINING THE INFORMATION **YOU WANT** TO BE INCLUDED ON YOUR DRUG'S PRESCRIBING INFORMATION. AT THE BOTTOM TIP IS THE DRUG ITSELF, AND ACROSS THE ARE FALLING SUCCESS RATES PARTLY TO BLAME?


EUROPE



THREE FOUNDATIONAL QUESTIONS »

BROAD TOP IS THE PRESCRIBING INFORMATION. EVERYTHING IN BETWEEN IS DRUG DEVELOPMENT.

FORM THE BASE OF A **COMPREHENSIVE DRUG DEVELOPMENT STRATEGY** BY CONSIDERING THESE QUESTIONS.



2013.pdf. 2. Levine, Daniel S. New Estimate of Drug Development Costs Pegs Total at \$1.5 Billion. December 7, 2012. Available at:http://www.burrillreport.com/article-new_estimate_of_drug_development_costs_ pegs_total_at_1_5_billion.html.3. King, Simon. FirstWord Lists FDA drug approvals in 2013: Cause for industry optimism? January 5, 2014. Available at:http://www.firstwordphar-ma.com/node/1180426#axzz-2/01Ld7Dz. 4. Novel New Drugs 2013 Summary. Federal Food and Drug Administration Center for Drug Evaluation and Research. Available at: http://www.firstwordphar-ma.com/node/1180426#axzz-DrugInnovation/UCM381803.pdf